SCHEMBL23375810

SCHEMBL23375810

C[C@@]1(c2ccccc2)CC1C(=O)N1C(=O)OC[C@@H]1c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
GAA P10253 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 1/20 0.36
NAAA Q02083 1/20 0.35
OPRM1 P35372 3/20 0.34
OPRK1 P41145 1/20 0.34
RIPK1 Q13546 2/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
IDH1 O75874 1/20 0.34
HDAC1 Q13547 2/20 0.33
AVPR1A P37288 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21447498 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL21447258 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL21447496 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL21447237 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL23357302 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL21447259 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL23357120 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL23356926 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL21447473 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1
SCHEMBL21447256 1.00 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352316-B2 Opioid receptor modulators and products and methods related thereto EPIODYNE, INC. (US) 2022-06-07 US disclosed
US-20210163402-A1 OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO EPIODYNE, INC. 2021-06-03 US disclosed
US-20210147343-A1 OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO EPIODYNE, INC. 2021-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352316-B2 Opioid receptor modulators and products and methods related thereto OPRM1, OPRD1, OPRK1 LMNA 3394/4885SMN1; SMN2 3077/4885ALDH1A1 1571/4885
US-20210163402-A1 OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO OPRM1, OPRD1, OPRK1 LMNA 3394/4885SMN1; SMN2 3077/4885ALDH1A1 1571/4885
US-20210147343-A1 OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO OPRM1, OPRD1, OPRK1 LMNA 3162/4885SMN1; SMN2 3470/4885ALDH1A1 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.